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ABSTRACT 1 
The ultimate goal of chemotherapy is to achieve a cure without causing any adverse effects.	 2 
We have developed pH-sensitive redox nanoparticle (RNPN), which disintegrates under acidic 3 
conditions and exposes nitroxide radicals, leading to strongly scavenging reactive oxygen species 4 
(ROS).  After intravenous administration of RNPN to tumor bearing mice, it effectively 5 
accumulated in tumor due to the leaky neovascular and immature lymphatic system and 6 
scavenged ROS, resulting in suppression of inflammation and activation of NF-κB, after 7 
disintegration of RNPN in tumor. Pre-administration of RNPN prior to treatments with anticancer 8 
agents, doxorubicin, to tumor-bearing mice significantly suppressed a progression of tumor size, 9 
compared to low-molecular weight 4-hydroxy-TEMPO.  Interestingly, the administration of 10 
RNPN suppressed adverse effects of doxorubicin to normal organs due to the scavenging ROS 11 
and suppression of inflammation, which was confirmed by reduction in lactate dehydrogenase 12 
and creatine phosphokinase activities in plasma. RNPN is thus anticipated as novel and ideal 13 
adjuvant for cancer chemotherapy. 14 
 15 
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 19 
Introduction 20 
Despite years of anticancer drug development, including that of molecularly targeted 21 
therapeutics with their ability to selectively interfere with certain hallmarks of cancer, no perfect 22 
anticancer drug has been developed thus far.  Cancer cells are known to develop drug resistance 23 
with repeated drug administrations.  Recently, chronic inflammation of the tumor 24 
microenvironment has been reported to influence such drug resistance [1, 2] .  Reactive oxygen 25 
species (ROS) generated in this region play an important role [3].  Elevated rates of ROS have 26 
been detected in almost all cancers [4], in which they activate transcription factors, such as 27 
nuclear factor-kappa B (NF-κB). It has been reported that this NF-κB promotes many aspects of 28 
tumor development and progression including an anti-apoptosis effect and drug resistance [5-7].  29 
Interestingly, a large number of anticancer drugs such as the anthracyclines (e.g., doxorubicin 30 
[DOX] epirubicin, and daunorubicin), alkylating agents, platinum coordination complexes (e.g., 31 
cisplatin, carboplatin, and oxaliplatin), epipodophyllotoxins (e.g., etoposide and teniposide), and 32 
camptothecins (e.g., topotecan and irinotecan), generate ROS in vivo, resulting in severe adverse 33 
effects in normal tissues [8, 9].  At the same time, these anticancer drugs increase oxidative 34 
stress in tumor microenvironments and further increase drug resistance in this region. The 35 
suppression of inflammation in the tumor microenvironment is one of the suitable targets for 36 
decreasing drug resistance of tumor [9-13].  Several approaches have been reported thus far, 37 
using anti-inflammatory agents and ROS scavengers such as dexamethasone (DEX) [10-12], 38 
edaravone [13], and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) [14]; pretreatment with 39 
anti-inflammatory agents or ROS scavengers increases the antitumor activity of anticancer drugs.  40 
However, in vivo, low-molecular-weight (LMW) drug-based approaches have limited potential 41 
because they are rapidly excreted by the kidney [15], resulting in a lower concentration of drug 42 
in the tumor area and severe adverse effects in normal tissue; for example, TEMPO derivatives 43 
cause dramatic decrease in blood pressure after administration [16].  Additionally, a high 44 
enough amount of LMW ROS scavengers cannot be used for the suppression of oxidative stress 45 
in the tumor microenvironment, because LMW-TEMPO derivatives induce mitochondrial 46 
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dysfunction due to inessential redox reactions in the cells [17, 18]. 1 
To address these issues, we have focused on redox polymer therapeutics by using a nitroxide 2 
radical-containing nanoparticle (RNP).  We developed pH-sensitive RNP (RNPN), which is a 3 
core-shell type of self-assembling polymeric micelle that is 40 nm in diameter, prepared using 4 
poly(ethylene glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene] 5 
(PEG-b-PMNT) diblock copolymer in aqueous media (Figure 1) [19-22].  As the leakage of the 6 
drugs from the nanoparticle into the blood stream would decrease its therapeutic efficiency and 7 
cause severe adverse effects, TEMPO moieties were covalently conjugated to the hydrophobic 8 
segment of the amphiphilic block copolymer (PEG-b-PMNT).  There are two main concepts 9 
regarding RNPN for delivering the nitroxide radical TEMPO to the tumor site and effectively 10 
scavenging ROS.  First, RNPN exhibits long blood circulation time in vivo because of the 11 
nanometer-sized structure and high biocompatibility of the PEG outer shell of RNPN, resulting in 12 
the accumulation of RNPN in inflamed sites including the tumor area, because of the leaky 13 
neovascular vessels in this area. Second, RNPN disintegrates in response to acidic conditions 14 
owing to the protonation of amino groups in the PMNT segments. Because of hypoxic effect in 15 
tumor microenvironment, extracellular region of tumor is also acidic due to the increased 16 
glycolytic system, referred to as Warburg effect [23]. Consequently, RNPN must disintegrate not 17 
only in endosome and lysosome but also in extracellular region of tumor, resulting in increased 18 
ROS scavenging activity. Moreover, the adverse effect of LMW nitroxide radicals is markedly 19 
suppressed as a result of the compartmentalization of nitroxide radicals in the core of RNPN in 20 
the bloodstream.  Given these characteristics, it has so far been confirmed that RNPN shows not 21 
only a suppressive effect on oxidative stress in cellular studies [24, 25] but also a therapeutic 22 
effect against ischemia reperfusion injury and intracerebral hemorrhage through intravenous 23 
administration in vivo [26-28]. If RNPN accumulates in tumor sites and scavenges ROS 24 
effectively, drug resistance of tumor can be successfully prevented by the suppression of NF-κB 25 
activation. Another issue in the field of cancer chemotherapy is that the adverse effects of 26 
anticancer drugs continue to trouble patients; for example, DOX causes severe cardiovascular 27 
toxicity during chemotherapy.  As stated previously, since RNPN tends to improve blood 28 
circulation, which increases accumulation in inflamed sites and effectively suppresses 29 
inflammation by scavenging the generated ROS in these sites, adverse effects may decrease 30 
because of the suppression of ROS caused by DOX in normal tissues.  In this study, we 31 
investigated the treatment effects of RNPN on both the anti-tumor activity of DOX and 32 
DOX-induced cardiotoxicity in vivo. 33 
 34 
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 1 
Figure 1.  Schematic illustration of (a) pH-sensitive RNPN, which is a core-shell type of 2 
self-assembling polymeric micelle that is 40 nm in diameter and prepared using poly(ethylene 3 
glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene] (PEG-b-PMNT) 4 
amphiphilic diblock copolymers; and (b) the effective accumulation and disintegration of RNPN 5 
in the tumor area 6 
 7 
 8 
Material and Methods 9 
Preparation of RNPN  10 
pH-responsive RNPN was prepared using self-assembling PEG-b-PMNT block copolymers, as 11 
previously reported [20]. Please see Supplementary Methods about detailed description of the 12 
method.  13 
 14 
Animal 15 
The experiments on the enhancement of anticancer activity and cardiotoxicity of DOX 16 
were carried out using BALB/c (4 weeks old, male, approximately 25 g) and ICR mice (7 weeks 17 
old, male, approximately 35 g), respectively, that were purchased from CHARLES RIVER 18 
JAPAN, Inc.  Mice were maintained in the experimental animal facilities at the University of 19 
Tsukuba.  All mice were housed in a temperature- and humidity-controlled, 12-h light:12-h 20 
dark environment.  All mice were fed commercial chow and water ad libitum.  All 21 
experiments were performed according to the Guide for the Care and Use of Laboratory Animals 22 
of the University of Tsukuba.  23 
 24 
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Electron spin resonance (ESR) measurement of nitroxide radical concentration in blood 1 
and tumors. 2 
The biodistribution of the nitroxide radicals in the RNPN in tumor-bearing mice was 3 
evaluated using ESR.  The tumor-bearing mice were prepared with a subcutaneous injection of 4 
murine colon adenocarcinoma 26 (colon-26) cells (1 × 106 cells/mouse) into their right thigh. 5 
When the volume of the tumor reached 100 mm3, RNPN (300 mg/kg) or 4-hydroxy-TEMPO 6 
(TEMPOL) (40 mg/kg) was administered to the tumor-bearing mice by intravenous injection.  7 
It should be noted that the concentrations of nitroxide radicals in all drugs were the same, which 8 
were adjusted using ESR measurements.  Blood samples were collected from the heart using a 9 
heparinized syringe at 0.083, 0.25, 1, 3, 6 and 24 h after administration, and the tumor was 10 
excised immediately after blood collection.  The blood and tumor were immediately placed on 11 
ice.  Plasma samples were then obtained by centrifuging (6,200 rpm, 2000 g, for 10 min) the 12 
blood samples.  To determine the ESR intensities at 0 min, 12.5 μL of RNPN solution (30 13 
mg/mL) was added to the blood (100 μL), followed by centrifugation (6,200 rpm, 2000 g, for 10 14 
min) of the blood and the measurement of ESR, assuming that the total blood volume in mice is 15 
80 mL/kg.  The tumor tissue homogenates were prepared using an ultra-sonic homogenizer 16 
(UH-50; SMT Company, Tokyo, Japan).   17 
Nitroxide radicals are reduced to hydroxylamine, which has no ESR signal, by an in vivo 18 
reducing agent such as ascorbic acid.  As hydroxylamine also possesses ROS-scavenging 19 
capacity, the total drug concentrations (nitroxide radicals + hydroxylamines) in blood and tumor 20 
were determined by the addition of potassium ferricyanide (K3[Fe(CN)6]) (200 mM, 20 μL) to 21 
plasma (200 μL) or the tumor homogenate sample (200 mg) to re-oxidize the hydroxylamines to 22 
nitroxide radicals.  Using an X-band ESR spectrometer (JES-TE25X; JEOL, Tokyo, Japan), the 23 
ESR measurements were carried out under the following conditions: frequency, 9.41 GHz; 24 
power, 8.00 mW; field, 333.8 ± 5 mT; sweep time, 1.0 min; modulation, 0.1 mT; and time 25 
constant, 0.1 s. 26 
 27 
In vivo antitumor activity studies  28 
Tumor-bearing mice were randomly divided into various treatment and control groups (5 29 
mice/group).  Animals were treated with saline, RNPN (100 mg/kg) or LMW-TEMPOL (13.3 30 
mg/kg) by intravenous injection once per day for 4 days before chemotherapy (days -4 to -1).  31 
DOX was administered intravenously at a single dose of 10 mg/kg on day 0.  Antitumor activity 32 
was evaluated in terms of tumor volume (V), which was calculated using the following equation: 33 
Tumor volume (V) = 0.52 × L × W2 34 
L and W are the long diameter and the short diameter of the tumor, respectively, as measured by 35 
a caliper. 36 
 37 
Western blot analysis. 38 
The protein levels of nuclear NF-κB (p65) were measured by Western blotting.  The 39 
colon 26 cell was used for the in vitro study, similar to the in vivo study using tumor-bearing 40 
mice.  The protein from control and RNPN-treated cells was extracted using a nuclear extraction 41 
kit (Cayman Chemical Company, Ann Arbor, MI, USA) according the manufacturer’s protocol.  42 
Protein estimation was carried out using the Thermo Scientific Pierce BCA Protein Assay Kit 43 
(Rockford, IL, USA).  Approximately 20 µL of protein sample was electrophoresed in a 15% 44 
polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Richmond, CA, 45 
USA) by electroblotting.  The membrane was blocked for 1 h with 1% BSA and probed with 46 
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the primary and secondary antibodies.  Luminata™ Western HRP Substrate (EMD Millipore 1 
Corporation, Billerica, MA, USA) was used to develop the membrane and the protein 2 
concentrations were estimated.  Each blot was stripped and reprobed for β-actin for equal 3 
protein loading detection. 4 
 5 
Evaluation of the suppressive effect of RNPN on cardiotoxicity caused by DOX 6 
The ICR mice were randomly divided to receive an intravenous injection of DOX (20 7 
mg/kg) 30 min after the intravenous injection of RNPN (25 mg/kg), LMW-TEMPOL (4 mg/kg), 8 
or phosphate-buffered saline (PBS), followed by 2 intravenous injections of RNPN (25 mg/kg), 9 
LMW-TEMPOL (4 mg/kg), or PBS at 24 and 48 h after DOX administration.  At 72 h after 10 
DOX administration, the mice were anesthetized and blood samples were collected by 11 
intracardiac puncture using a heparinized syringe.  Plasma samples were then obtained by 12 
centrifugation (6,200 rpm, 2000 g, for 10 min) of the blood.  Plasma samples were assayed for 13 
plasma lactate dehydrogenase (LDH) and plasma creatine phosphokinase (CPK) activities using 14 
a Fuji Dri-chem 3500 analyzer (Fuji-Film, Tokyo, Japan).  To determine the amounts of lipid 15 
peroxidation and supeoxide induced by DOX, heart tissues were excised from mice after the 16 
blood samples were collected.  Plasma and heart tissue were frozen and stored at -80 °C until 17 
the further use. 18 
 19 
Measurement of levels of superoxide anion, TNF-α, and malonyldialdehyde (MDA) 20 
Please see Supplementary Methods about detailed description of the method.  21 
 22 
Statistical analysis 23 
All values are expressed as mean ± standard error of mean (SEM).  Differences 24 
between two groups were examined for statistical significance by using the Student’s t test.  25 
Differences between more than three groups were examined for statistical significance by using 26 
one-way ANOVA followed by Tukey’s test (SPSS software; IBM Corp, Armonk, NY, USA). A 27 
P value of <0.05 was considered significant for all of these statistical analyses. 28 
 29 
Results  30 
Biodistribution of RNPN and its morphological change in tumor sites 31 
PEG-b-PMNT block copolymers were prepared as previously reported [20]. RNPN was prepared 32 
by self-assembly of the synthesized amphiphilic block copolymer, PEG-b-PMNT, via the 33 
dialysis method against water, with an average diameter of about 40 nm (polydispersity factor, 34 
µ/Γ 2 = 0.04).  To examine the biodistribution of RNPN and LMW-TEMPOL in tumor-bearing 35 
mice, we measured the concentration of nitroxide radicals in the blood and tumor area by ESR, 36 
because nitroxide radicals are susceptible to ESR.  Figure 2a shows the time profile of the drug 37 
concentration of RNPN and LMW-TEMPOL in the blood.  Contrary to the rapid clearance of 38 
LMW LMW-TEMPOL from the bloodstream, the ESR signals of RNPN were observed for a 39 
relatively long period of time.  The AUC value of RNPN in blood (AUC: 769.49) was much 40 
higher than that of LMW-TEMPOL (AUC: 19.2).  The rapid clearance of LMW-TEMPOL 41 
might be attributed to preferential renal clearance and diffusion across the entire body.  Figure 42 
2b shows the accumulation amounts of RNPN and LMW-TEMPOL in tumors.  The 43 
accumulation level of RNPN in the tumor tissues of mice at 24 h after intravenous administration 44 
was 3.3% ID/g tumor tissue, whereas that of LMW-TEMPOL at 24 h after injection was only 45 
0.4% ID/g tumor tissue. Although the accumulation tendency of RNPN was not markedly higher 46 
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than that of RNPO, another nitroxide radical-containing nanoparticles that is not pH-sensitive and 1 
has high colloidal dispersion stability (see Figures S1 and S2), the AUC of RNPN in tumor 2 
tissues (AUC: 39.6) was still 6 to 7 fold higher than that of LMW-TEMPOL (AUC: 6.5).  This 3 
indicated the clear accumulation of nanoparticles in tumors because of the increased vascular 4 
permeation and immature lymphatic excretion (the so-called enhanced permeability and retention 5 
[EPR] effect [29]).  The moderate accumulation tendency of RNPN is probably due to the 6 
pH-disintegration characteristics (see below) of the polyamine segment, which may loosen its 7 
coagulation force coagulation force of hydrophobic interaction in the core by increasing its 8 
hydrophilicity.  The validity of our strategy regarding the covalent conjugation of bioactive 9 
species, nitroxide radicals, in this case, was demonstrated.  If the physical entrapment of 10 
TEMPO molecules in pH-sensitive nanoparticles is used, they must leak easily during circulation 11 
due to the loosened core. 12 
 The ESR spectra of RNPN can provide information on morphological changes in vivo.  13 
The ESR signal of LMW-TEMPO derivatives shows a sharp triplet due to an interaction between 14 
the 14-nitrogen nuclei and the unpaired electron in the dilute solution. At 15 min after the 15 
intravenous administration of LMW-TEMPOL to mice, clear triplet signals were observed both 16 
in blood and in tumors, as shown in Figures 2c and 2d.  In contrast, the ESR signal of RNPN in 17 
the blood stream showed a broad spectrum, because of the confinement of the nitroxide radicals 18 
in the solid core of RNPN (Figure 2e).  As shown in Figure 2f, the triplet signals were observed 19 
in tumor, indicating the disintegration of RNPN in this area and the exposed nitroxide radicals 20 
outside of the particle, which is probably due to the acidic tumor microenvironment.  In fact, no 21 
changes in ESR signals for both blood and tumor were observed for RNPO (Figure S3), leading 22 
us to strongly anticipate an increase in the reactivity of the nitroxide radicals of RNPN to ROS in 23 
tumors as a result of its disintegration at the tumor sites. 24 
   25 
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 1 
Figure 2.  (a,b) Distribution profiles of RNPN (white circle) and low-molecular-weight (LMW) 2 
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL) (block triangle) in (a) blood and (b) 3 
tumor tissue from tumor-bearing mice, as determined by electron spin resonance (ESR) 4 
measurement. The data are expressed as means ± SEM; n = 5.  (c-f) The ESR spectra of (c) 5 
LMW-TEMPOL in blood, (d) LMW-TEMPOL in tumor, (e) RNPN in blood, and (f) RNPN in 6 
tumor at 15 min after intravenous administration are shown.  All samples were oxidized by 7 
potassium ferricyanide (K3[Fe(CN)6]). 8 
 9 
 10 
Pretreatment of tumor-bearing mice with RNPN enhances the therapeutic effects of DOX in 11 
vivo 12 
    Having confirmed that RNPN accumulates and disintegrates in tumor regions, we 13 
investigated the effect of RNPN on the expression of NF-κB in cancer cells.  Figure 3 shows the 14 
expression level of NF-κB in the nuclei of colon-26 cells with and without RNPN treatment.  In 15 
contrast to the high expression level of NF-κB observed in the nuclei of tumor cells, the 16 
expression level of NF-κB was suppressed, in a dose-dependent manner, on administration of 17 
RNPN, clearly indicating the effectiveness of RNPN in suppressing this transcription factor in 18 
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colon-26 cells. 1 
 2 
 3 
Figure 3.  Suppressive effects of RNPN on the activation of NF-κB.  (a) Western blot analysis 4 
of NF-κB expression in colon-26 cells treated with RNPN.  (b) The graph represents the 5 
densitometry average of three representative blots.  Values are expressed as mean ± SEM.  *P 6 
< 0.05 compared with controls; Student’s t-test; n = 3. 7 
  8 
 Given the significant effect of RNPN observed on the suppression of inflammatory 9 
transcription factor NF-κB, we investigated the pharmacological effect of the anticancer drug, 10 
DOX, after pretreatment of tumor-bearing mice with RNPN. Here, RNPN was administered for 4 11 
days to suppress the NF-κB activation before DOX treatment. First, we measured the suppressive 12 
effect of RNPN treatment on superoxide generation in the tumor area.  Because PEG-b-PMNT 13 
possesses nitroxide radicals, it scavenges ROS such as superoxide and hydroxyl radicals [30].  14 
When tumor-bearing mice were treated with intravenous injections of RNPN at a dose of 100 15 
mg/kg for 4 days, the levels of ROS were found to be significantly decreased in tumors 16 
compared with controls (saline administration); this is in sharp contrast to the results observed 17 
with administration of LMW-TEMPOL (Figure 4a).  The suppression of oxidative stress in the 18 
tumor microenvironment was also confirmed by the measurement of the proinflammatory 19 
cytokine, TNF-α.  As seen in Figure 4b, the suppressive effect of RNPN treatment on level of 20 
10 
 
TNF-α was higher than that of LMW-TEMPOL. These findings underline the importance of 1 
local ROS scavenging by RNPN, which results in the suppression of cytokine levels and NF-κB 2 
activation [31], resulting in the inhibition of tumor resistance. 3 
 4 
 5 
Figure 4.  Suppressive effect of pretreatment with RNPN on the generation of superoxide 6 
anions and TNF-α in tumors.  (a) Amounts of superoxide in tumor tissue were measured using 7 
dihydroethidium (DHE).  Superoxide values were expressed as the value related to the 8 
fluorescent intensity of the saline group.  Values are expressed as mean ± SEM.  *P < 0.05 9 
compared with the saline group; ANOVA; n = 5.  (b) The concentration of TNF-α in tumor was 10 
measured by enzyme-linked immunosorbent assay (ELISA). Values are expressed as mean ± 11 
SEM.  *P < 0.05 compared with the saline group; ANOVA; n = 10. 12 
 13 
      Having demonstrated the suppression of inflammation in the tumor microenvironment 14 
and the activation of inflammatory transcription factor NF-κB, we then examined the enhancing 15 
effect of RNPN on the anti-tumor activity of DOX.  Tumor-bearing mice were treated with 16 
intravenous injections of RNPN at a dose of 100 mg/kg for 4 days (days -4 to -1), followed by the 17 
intravenous injection of DOX (10 mg/kg, day 0).  Tumor progression was analyzed as shown in 18 
Figure 5.  When LMW-TEMPOL was administered intravenously and followed by DOX 19 
administration, almost no effect was observed.  Although it was previously reported that the 20 
intratumoral administration of TEMPO in tumor-bearing mice inhibits tumor growth by inducing 21 
apoptosis [14], the intravenous administration of LMW-TEMPOL in tumor-bearing mice did not 22 
show any effect under the present study conditions.  The reason for these results may stem from 23 
a lower intratumoral concentration of nitroxide radicals because of rapid renal clearance and 24 
diffusion throughout the entire body.  In contrast, a remarkably large effect was observed with 25 
the administration of RNPN prior to DOX administration.  Interestingly, a much higher adjuvant 26 
effect of RNPN on the anti-tumor activity of DOX was observed in vivo compared with that of 27 
RNPO, although the tumor accumulation of RNPO was much higher than that of RNPN (Figure 28 
S4).  This result indicates that both accumulation tendency and pH-triggered disintegration 29 
characteristics of RNPN are important to effectively suppress the activation of NF-κB and 30 
decrease the resistance of tumor cells.  Similar effects were observed with the pretreatment of 31 
RNPN prior to the administration of other anticancer drugs, carboplatin (Figure S5).   32 
 33 
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 1 
Figure 5.  Effect of RNPN pretreatment on the antitumor activity of doxorubicin (DOX) in 2 
BALB/c mice bearing colon-26 tumors.  Animals were intravenously pretreated with RNPN 3 
(100 mg/day for 4 days, days -4 to -1).  DOX was intravenously administered at a single dose of 4 
10 mg/kg on day 0.  Tumor size is expressed as mean ± SEM. ∗P < 0.05 compared with DOX 5 
alone; Student’s t-test; n = 5. 6 
 7 
 8 
Suppression of adverse effects of DOX by RNPN  9 
DOX is known to cause cardiotoxicity through the generation of ROS as stated previously.  10 
We have already confirmed that RNPs tend to accumulate in inflammation sites and effectively 11 
suppress inflammation by scavenging ROS generated in these sites [32].	  If RNPN suppresses 12 
the adverse cardiotoxic effects of DOX in addition to inhibiting tumor progression, it would be 13 
an ideal cancer chemotherapy system.  To examine the cardiotoxicity of DOX, CPK and LDH 14 
activities were measured.  CPK, LDH, which are indicator of myocardial damage, are released 15 
from the heart muscle cells when it is injured. Here, RNPN or LMW-TEMPOL was administered 16 
three times before and after DOX treatment because DOX generates ROS continuously not only 17 
in tumor region but also in healthy organs such as heart and liver.  As shown in Figures 6a and 18 
6b, compared to that of mice given a tail vein injection of PBS, mice treated with a single dose of 19 
DOX (20 mg/kg) showed a 5-fold increase in plasma CPK activity and a 2.9-fold increase in 20 
plasma LDH activity.  Although the administration of LMW-TEMPOL showed decreases in 21 
plasma CPK and LDH activities to some extent in DOX-treated mice, no significant difference 22 
was found.  In contrast, the administration of RNPN (100 mg/kg) for 3 days remarkably 23 
suppressed cardiotoxicity in DOX-treated mice, as determined by reduction in CPK and LDH.  24 
We also investigated whether pretreatment with RNPN could scavenge ROS, particularly 25 
superoxide, generated in the heart at 24 h after DOX administration.  As shown in Figure 6c, 26 
the generation of ROS in heart tissue was significantly inhibited by RNPN treatment, regardless 27 
of the lack of effect observed with LMW-TEMPOL treatment.  Cardiotoxicity was also 28 
12 
 
investigated by determining the level of lipid peroxidation in the heart after DOX administration.  1 
When 20 mg/kg of DOX was administered intravenously, the level of MDA in the heart 2 
increased significantly (Figure 6d).  In contrast, no increase was observed with a 3-day 3 
RNPN-treatment before and after DOX administration; again, this is in sharp contrast to the 4 
findings obtained with LMW-TEMPOL.  These results can be attributed to the long circulation 5 
time of RNPN in blood and the accumulation of RNPN in the inflamed area, followed by the 6 
effective scavenging of ROS, resulting in the suppression of cardiotoxicity caused by DOX. 7 
 8 
 9 
Figure 6.  (a,b) Effect of treatment with RNPN or 10 
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL) on doxorubicin (DOX)-induced 11 
cardiotoxicity, as determined by measurement of the activities of (a) creatine phosphokinase 12 
(CPK) and (b) lactate dehydrogenase (LDH) in plasma.  The bar graphs represent means ± SEM, 13 
*P < 0.05 compared with DOX alone; Student’s t-test; n = 6. (c) Amounts of superoxide in heart 14 
tissue were measured using dihydroethidium (DHE).  Superoxide values were expressed as the 15 
value related to the fluorescent intensity of the control group.  Values are expressed as mean ± 16 
SEM.  *P < 0.05 compared with DOX alone; ANOVA; n = 4. (d) Effect of treatment with 17 
13 
 
RNPN or LMW-TEMPOL on malonyldialdehyde (MDA) activity in the heart tissue of ICR mice 1 
after DOX administration.  Values are expressed as mean ± SEM.  *P < 0.05 compared with 2 
DOX alone; Student’s t-test; n = 6. 3 
 4 
 5 
Discussion 6 
ROS are involved in the development of a wide spectrum of diseases, including chronic 7 
inflammation and cancers.  Anticancer drugs administered to cancer patients induce excessive 8 
oxidative stress, leading to further inflammation and ROS production.  This negative cycle 9 
induces the expression of transcription factors such as NF-κB and initiates many factors such as 10 
anti-apoptotic effects and drug resistance, leading to tumor development and progression; these 11 
factors lower the therapeutic effects of the anticancer drug and cause serious adverse effects.  A 12 
combination therapy of anticancer drugs with anti-inflammatory agents or ROS scavengers has 13 
been developed and applied in treatment. However, this therapy has not been very effective 14 
because of the rapid elimination of LMW drugs from the body via renal clearance [15] and the 15 
severe adverse effects of the drugs in normal tissues [16-18].   16 
In this study, we demonstrated that RNPN suppresses the activation of transcription factor, 17 
NF-κB in the cancer cells and improves the anticancer effect of DOX in vivo. These results 18 
indicate that long-term and effective ROS scavenging at the tumor site by RNPN pretreatment 19 
enhances the anticancer effect of the drug, because of effective accumulation and disintegration 20 
of RNPN in the tumor area.  Inflammatory cytokines are also suppressed by RNPN treatment.  21 
Production of ROS and inflammatory cytokines has been proven to be strongly associated with 22 
each other [33].  We have observed that ROS scavenging suppresses the production of 23 
inflammatory cytokines. RNPN showed an extended period of circulation in the blood and 24 
accumulation in inflamed areas, and the cardiac toxicity of DOX was reduced by RNPN treatment.  25 
Moreover, the anticancer activity and suppression of adverse effects was more remarkably 26 
enhanced by RNPN than by LMW-TEMPOL.  Since almost all the anticancer drugs have some 27 
drawbacks such as low efficiency and adverse effects, we believe that RNPN system can help 28 
design improved cancer treatments with good therapeutic outcomes, suppressing the adverse 29 
effects of the drugs. 30 
 31 
Conclusions  32 
    In conclusion, we have demonstrated that the pretreatment of our newly designed 33 
pH-responsive redox nanoparticle (RNPN), which tends to accumulate and disintegrate in tumor 34 
area, enhances the anti-tumor activity of DOX, because the exposed nitroxide radicals effectively 35 
scavenge ROS, which suppress the activation of NF-κB in this area. Our findings also showed 36 
that RNPN protects the cardiac damage by DOX in vivo. It should be noted that LMW-TEMPOL 37 
did not show these effects, which was probably due to its non-specific dispersion in entire body. 38 
This approach is based on the redox-nanoparticle assisted suppression of oxidative stress in 39 
tumor microenvironment, which may open a new paradigm for the design of improved cancer 40 
treatments with high chemotherapeutic outcomes, suppressing their adverse effects. 41 
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Figure Legends: 1 
 2 
Figure 1.  Schematic illustration of (a) pH-sensitive RNPN, which is a core-shell type of 3 
self-assembling polymeric micelle that is 40 nm in diameter and prepared using poly(ethylene 4 
glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene] (PEG-b-PMNT) 5 
amphiphilic diblock copolymers; and (b) the effective accumulation and disintegration of RNPN 6 
in the tumor area. 7 
 8 
Figure 2.  (a,b) Distribution profiles of RNPN (white circle) and low-molecular-weight (LMW) 9 
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL) (block triangle) in (a) blood and (b) 10 
tumor tissue from tumor-bearing mice, as determined by electron spin resonance (ESR) 11 
measurement. The data are expressed as means ± SEM; n = 5.  (c-f) The ESR spectra of (c) 12 
LMW-TEMPOL in blood, (d) LMW-TEMPOL in tumor, (e) RNPN in blood, and (f) RNPN in 13 
tumor at 15 min after intravenous administration are shown.  All samples were oxidized by 14 
potassium ferricyanide (K3[Fe(CN)6]). 15 
 16 
Figure 3.  Suppressive effects of RNPN on the activation of NF-κB.  (a) Western blot analysis 17 
of NF-κB expression in colon-26 cells treated with RNPN.  (b) The graph represents the 18 
densitometry average of three representative blots.  Values are expressed as mean ± SEM.  *P 19 
< 0.05 compared with controls; Student’s t-test; n = 3. 20 
 21 
Figure 4.  Suppressive effect of pretreatment with RNPN on the generation of superoxide 22 
anions and TNF-α in tumors.  (a) Amounts of superoxide in tumor tissue were measured using 23 
dihydroethidium (DHE).  Superoxide values were expressed as the value related to the 24 
fluorescent intensity of the saline group.  Values are expressed as mean ± SEM.  *P < 0.05 25 
compared with the saline group; ANOVA; n = 5.  (b) The concentration of TNF-α in tumor was 26 
measured by enzyme-linked immunosorbent assay (ELISA). Values are expressed as mean ± 27 
SEM.  *P < 0.05 compared with the saline group; ANOVA; n = 10. 28 
 29 
Figure 5.  Effect of RNPN pretreatment on the antitumor activity of doxorubicin (DOX) in 30 
BALB/c mice bearing colon-26 tumors.  Animals were intravenously pretreated with RNPN 31 
(100 mg/day for 4 days, days -4 to -1).  DOX was intravenously administered at a single dose of 32 
10 mg/kg on day 0.  Tumor size is expressed as mean ± SEM. ∗P < 0.05 compared with DOX 33 
alone; Student’s t-test; n = 5. 34 
 35 
Figure 6.  (a,b) Effect of treatment with RNPN or 36 
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL) on doxorubicin (DOX)-induced 37 
cardiotoxicity, as determined by measurement of the activities of (a) creatine phosphokinase 38 
(CPK) and (b) lactate dehydrogenase (LDH) in plasma.  The bar graphs represent means ± SEM, 39 
*P < 0.05 compared with DOX alone; Student’s t-test; n = 6. (c) Amounts of superoxide in heart 40 
tissue were measured using dihydroethidium (DHE).  Superoxide values were expressed as the 41 
value related to the fluorescent intensity of the control group.  Values are expressed as mean ± 42 
SEM.  *P < 0.05 compared with DOX alone; ANOVA; n = 4. (d) Effect of treatment with 43 
RNPN or LMW-TEMPOL on malonyldialdehyde (MDA) activity in the heart tissue of ICR mice 44 
after DOX administration.  Values are expressed as mean ± SEM.  *P < 0.05 compared with 45 
DOX alone; Student’s t-test; n = 6. 46 
